Clinical trial Recruiting at 4 sites Interventional

RNA and genome sequencing in trio approach to find and prioritize gene variants in neurodevelopmental disorders with developmental abnormalities

Official title: Transcriptomic Approach for the Identification and Prioritization of Genome Variants in Neurodevelopmental Disorders With Malformation

Run by University Hospital, Angers · NCT06762678 · Data updated 2026-11-12

Researchers test RNA sequencing together with trio whole-genome sequencing to help find disease-causing gene variants in people with neurodevelopmental disorders and developmental abnormalities, especially when standard tests have not identified a diagnosis.

Quick facts

Study typeInterventional
SexAll
Enrollment58 (estimated)
SponsorUniversity Hospital, Angers
Government
Locations7 sites (Angers and 6 other locations)
StatusRecruiting
StartedNovember 4, 2025
Main results expectedMay 4, 2028
Study endsMay 4, 2028
Registry record updatedJune 29, 2026
Trial IDNCT06762678 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children and adults with neurodevelopmental disorders who have unclear genetic diagnoses after prior chromosomal microarray or exome sequencing, and for whom skin biopsy/ RNA samples are available.

Probably not a fit

Patients whose disorders are not caused by detectable genomic or transcriptomic variants may not benefit from this approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study uses a multi-omic approach by performing RNA sequencing and trio whole-genome sequencing to identify and prioritize genome variants that may cause neurodevelopmental disorders with malformations. It targets individuals from birth through adulthood who have developmental delays, intellectual disability, autism, or related features and for whom prior genetic testing was inconclusive. The design integrates RNA data to reveal aberrant gene expression and other transcriptomic signals that can guide variant prioritization. The study is centered at French university hospitals and involves collaboration among Angers, Brest, and Le Mans sites. Ethical consent and fibroblast RNA samples are required for research use.

Why it matters

Potential benefit: If successful, the approach could increase diagnostic yield and help tailor management for individuals with neurodevelopmental disorders.

How similar studies have gone: Previous genomic and transcriptomic studies have shown added value in diagnosing complex neurodevelopmental conditions, though trio RNA/DNA approaches are less common and results vary by case.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria :

* children or adult without any age limit, with neurodevelopmental disorders defined by :
* between 0 and 5 years old with severe developmental delays regarding motor and/or language acquisitions, and/or social communication disorders,
* \> 6 years old with intellectual deficiency whatever the severity (with if available, neuropsychological evaluation), with potential associated manifestations such as epilepsy and/or autism, and/or behaviour troubles and/or attention deficit hyperactivity disorder ;
* with developmental anomalies and/or dimorphism ;
* without any evidence of clinical diagnosis
* negative chromosomal microarray and/or exome sequencing
* negative fragile X syndrome
* skin biopsy feasible or RNA sample extracted from fibroblast culture, available to be used in a research context inside the lab center
* consent obtained from the participant or, consent from legal representatives for a minor patient or a patient unable to consent
* participant affiliated to the french security regimen or equivalent

Exclusion Criteria:

* Neurodevelopmental disorders with developmental anomaly from non genetic causes or highly evident diagnosis for which a molecular test is available in routine practices and whose the cost is inferior than the cost of the genome and the RNA sequencing
* unwillingness to participate, from the patient or from the legal representatives
* Pregnant or lactating women

Where it's running

  • University Hospital of Angers
    Angers, France
    Recruiting
  • University Hospital of Brest
    Brest, France
    Recruiting
  • Le Mans Hospital Center
    Le Mans, France
    Recruiting
  • University Hospital of Rennes
    Rennes, France
    Recruiting
  • University Hospital of Nantes
    Nantes, France
    Not yet recruiting
  • University Hospital of Tours
    Tours, France
    Not yet recruiting
Show 1 more location
  • Vannes Hospital Center
    Vannes, France
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.